SG1906 for CLDN18.2-Positive Solid Tumors
Condition: Locally Advanced Unresectable or Metastatic Solid Tumors · Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
About this study
This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
This description comes directly from the study's public registry record.
Talk to the study team
Pengyu Shi · +86 010 56315401 · shipengyu@sumgenbio.com
Always discuss trial participation with your own doctor first.
Locations (9)
| Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital Of Xiamen University | Xiamen, Fujian, China | Recruiting |
| The Sixth Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Liaoning Cancer Hospital | Shenyang, Liaoning, China | Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05857332